Pramar Yahoda V, Mandal Tarun K, Bostanian Levon A, Kader Cyndy, Morris Tommy C, Graves Richard A
College of Pharmacy, Xavier University of Louisiana, New Orleans, Louisiana.
Int J Pharm Compd. 2023 Jul-Aug;27(4):330-339.
Azathioprine is used to treat the symptoms of rheumatoid arthritis and for the prevention of transplant rejection. A review of the therapeutic uses of Azathioprine reveals the need for flexibility in dosing. This flexibility is readily achieved using an oral liquid dosage form. However, no commercial liquid dosage form of Azathioprine currently exists. Azathioprine is commercially available only as a 50-mg tablet. An extemporaneously compounded suspension from pure drug powder would provide a flexible, customizable option to meet unique patient needs with convenient and accurate dosing options. The purpose of this study was to determine the physicochemical and microbiological stability of extemporaneously compounded Azathioprine suspensions in the PCCA Base, SuspendIt. This base is a sugar-free, paraben free, dye-free, and gluten-free thixotropic vehicle containing a natural sweetener obtained from the monk fruit. The study design included two Azathioprine concentrations to provide stability documentation over a bracketed concentration range for eventual use by compounding pharmacists. A robust stability-indicating high-performance liquid chromatographic assay for the determination of the chemical stability of Azathioprine in PCCA SuspendIt was developed and validated. Suspensions of Azathioprine were prepared in PCCA SuspendIt at 10-mg/mL and 50-mg/mL concentrations, selected to represent a range within which the drug is commonly dosed. Samples were stored in amber plastic prescription bottles at two temperature conditions (5°C and 25°C). Samples were assayed initially, and on the following time points (days): 7, 14, 28, 49, 63, 90, 119, and 182. Physical data such as pH, viscosity, and appearance were also noted. Microbiological stability was tested. All measurements were obtained in triplicate. A stable extemporaneous product is defined as one that retains at least 90% of the initial drug concentration throughout the sampling period and is protected against microbial growth. The study showed that Azathioprine concentrations did not go below 96.8% of the label claim (initial drug concentration) at both temperatures studied. No microbial growth was observed. The pH values remained constant. The viscosity of the suspensions allowed easy re-dispersal of the drug particles upon shaking. This study demonstrates that Azathioprine is physically, chemically, and microbiologically stable in PCCA SuspendIt for 182 days in the refrigerator and at room temperature, thus providing a viable, compounded alternative for Azathioprine in a liquid dosage form, with an extended beyond-use date to meet patient needs.
硫唑嘌呤用于治疗类风湿性关节炎症状及预防移植排斥反应。对硫唑嘌呤治疗用途的综述表明给药需具备灵活性。使用口服液体制剂可轻松实现这种灵活性。然而,目前尚无硫唑嘌呤的商业液体制剂。硫唑嘌呤仅以50毫克片剂形式在市场上销售。由纯药物粉末临时配制的混悬液将提供一种灵活、可定制的选择,通过方便且准确的给药方式满足患者的独特需求。本研究的目的是确定在PCCA赋形剂SuspendIt中临时配制的硫唑嘌呤混悬液的物理化学和微生物稳定性。这种赋形剂是一种无糖、无对羟基苯甲酸酯、无染料且无麸质的触变载体,含有从罗汉果中提取的天然甜味剂。研究设计包括两种硫唑嘌呤浓度,以便在一个括弧浓度范围内提供稳定性记录,供配制药剂师最终使用。开发并验证了一种用于测定硫唑嘌呤在PCCA SuspendIt中的化学稳定性的稳健的稳定性指示高效液相色谱法。硫唑嘌呤混悬液在PCCA SuspendIt中分别以10毫克/毫升和50毫克/毫升的浓度配制,所选浓度代表该药物常用的给药范围。样品储存在琥珀色塑料处方瓶中,置于两种温度条件下(5℃和25℃)。最初对样品进行检测,并在以下时间点(天数)检测:7、14、28、49、63、90、119和182。还记录了诸如pH值、粘度和外观等物理数据。测试了微生物稳定性。所有测量均重复三次。一种稳定的临时产品定义为在整个采样期内至少保留初始药物浓度的90%且能防止微生物生长的产品。研究表明,在所研究的两种温度下,硫唑嘌呤浓度均未低于标签标示量(初始药物浓度)的96.8%。未观察到微生物生长。pH值保持恒定。混悬液的粘度使药物颗粒在振荡后易于重新分散。本研究表明,硫唑嘌呤在PCCA SuspendIt中在冰箱和室温下182天内物理、化学和微生物性质稳定,从而为液体剂型的硫唑嘌呤提供了一种可行的配制替代品,其超出有效期延长,可满足患者需求。